$0.14
+0.01 (+3.70%)
Open$0.13
Previous Close$0.14
Day High$0.14
Day Low$0.13
52W High$1.40
52W Low$0.10
Volume—
Avg Volume1.84M
Market Cap2.18M
P/E Ratio—
EPS$-2.06
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+17,857.1% upside
Current
$0.14
$0.14
Target
$25.14
$25.14
$18.28
$25.14 avg
$30.13
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 204.9K | 501.7K | 427.8K |
| Net Income | -245,012,378 | -539,806,952 | 33.9K |
| Profit Margin | -119,566.5% | -113,588.2% | 7.9% |
| EBITDA | -244,197,285 | -567,900,662 | 68.2K |
| Free Cash Flow | — | — | 23.2K |
| Rev Growth | -59.2% | -59.2% | +6.7% |
| Debt/Equity | 0.00 | 0.00 | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $250.82 | +0.83% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $417.84 | +0.40% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.14 | +1.67% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $516.44 | -1.77% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $805.97 | +1.00% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.12 | +1.42% | 35.2 | 28.41B |